Product Images Lamotrigine Extended Release

Each extended-release film-coated tablet of Lamotrigine USP contains 100 mg. Lamotrigine is indicated for the treatment of epilepsy and bipolar disorder. The usual dosage instructions are provided in the prescribing information. The product should be stored at 20° to 25°C (68° to 77°F), and excursions permitted to 15°to 30°C (59° to 86°F). The product is manufactured by TruPharma LLC and 30 tablets are available in a bottle. It is important to dispense the accompanying medication guide to each patient.*

Each extended-release film-coated tablet contains 200mg of lamotrigine USP. The medication is prescribed once a day, and dosage information can be found in the prescribing information. The tablets should be stored at temperatures between 20°C to 25°C (68°F to 77°F) and kept out of direct sunlight. If the seal under the cap is broken, do not use the medication. This product is manufactured for TruPharma, LLC and caution must be taken to verify the product dispensed. The medication guide should be given to each patient. The pack contains 30 tablets.*

This is a description of a medication package containing 30 extended-release film-coated tablets, each containing lamotrigine USP at a strength of 25 mg. The usual dosage instructions should be obtained from the prescribing information. The product should not be used if the safety seal under the cap is broken or missing, and it should be stored within a specified temperature range. The medication is manufactured by TruPharma, LLC and is available only by prescription. A medication guide should be provided to each patient. No further information is available.*

This is a description of a medication called Lamotrigine, which is present in each extended-release film-coated tablet of 50mg strength. The tablets are manufactured by TruPharma and come in a bottle of 30 tablets. The medication should be stored between 20° to 25°C and can have excursions permitted to 15° to 30°C. There is a warning to verify the product dispensed. The medication information should be provided to each patient.*

This text appears to be a graph of some sort, displaying the effectiveness and results of two drugs or treatments. The names "Placebo" and "Lamotigine" can be seen with percentage values and numbers listed beneath them. Without more context or a clearer image, it is difficult to provide more specific information.*

The given text seems to be a statistical chart, displaying Responder Rate (Equal or Greater) of two treatments: Plasebo and ZZ Gimotigie ER. The chart shows the percentage of improvement and worsening in both treatments with four responders or more. The improvement rate in Plasebo is 75%, while in ZZ Gimotigie ER, it is 100%. There is no information available for the worsening rate in Plasebo, and in ZZ Gimotigie ER, it is 50%. The chart also displays the percentage of patients corresponding to different response rates from 0% to 60%.*

Lamotrigine extended-release tablets are a medication available in four different dosages: 25mg, 50mg, 100mg, and 200mg. Each dose comes in a different colored, round tablet with a unique imprint. The 25mg tablet is white or off-white with an imprint of H008. The 50mg tablet is peach and has an imprint of H009. The 100mg tablet is yellow and imprinted with Ho12. Lastly, the 200mg tablet is blue with an imprint of HO11.*